FKBP12-mediated degradation of MDM2 confers continuing and constitutive activation of p53, suppression of XIAP, and consequent sensitization of cancer cells to the cytotoxic and apoptotic effects of doxorubicin. This evidence concerns the gene TP53 and cancer.